Literature DB >> 18500471

[Biologics in the early treatment of ankylosing spondylitis and related forms of spondyloarthritis].

Hans-Eckhard Langer1.   

Abstract

New pathogenetic insights have identified the key role of TNF-alpha in inflammatory rheumatic diseases and have revolutionized the therapy of spondyloarthritides. TNF-alpha-antagonists specifically inhibit the pro-inflammatory effects of TNF-alpha. Clinical studies with infliximab (Remicade), Etanercept (Enbrel) or Adalimumab (Humira) in ankylosing spondylitis or related diseases demonstrate superior efficacy to conventional drugs like non-steroidal antirheumatic drugs or traditional disease modifying antirheumatic drugs.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18500471     DOI： 10.1007/s10354-008-0522-2

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  68 in total

1.  Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up.

Authors:  E Kruithof; F Van den Bosch; D Baeten; A Herssens; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

2.  Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.

Authors:  F Van den Bosch; E Kruithof; D Baeten; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

3.  Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.

Authors:  X Baraliakos; J Brandt; J Listing; H Haibel; H Sörensen; M Rudwaleit; J Sieper; J Braun
Journal:  Arthritis Rheum       Date:  2005-12-15

Review 4.  Methotrexate for ankylosing spondylitis.

Authors:  J Chen; C Liu; J Lin
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

5.  Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept.

Authors:  M Rudwaleit; X Baraliakos; J Listing; J Brandt; J Sieper; J Braun
Journal:  Ann Rheum Dis       Date:  2005-03-18       Impact factor: 19.103

6.  Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study.

Authors:  D Biasi; A Carletto; P Caramaschi; M L Pacor; T Maleknia; L M Bambara
Journal:  Clin Rheumatol       Date:  2000       Impact factor: 2.980

7.  Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study.

Authors:  M Breban; E Vignon; P Claudepierre; V Devauchelle; D Wendling; E Lespessailles; L Euller-Ziegler; J Sibilia; A Perdriger; M Mezières; C Alexandre; M Dougados
Journal:  Rheumatology (Oxford)       Date:  2002-11       Impact factor: 7.580

Review 8.  Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.

Authors:  Arthur Kavanaugh; Zuhre Tutuncu; Teresa Catalan-Sanchez
Journal:  Curr Opin Rheumatol       Date:  2006-07       Impact factor: 5.006

9.  Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

Authors:  John C Davis; Désirée Van Der Heijde; Jurgen Braun; Maxime Dougados; John Cush; Daniel O Clegg; Alan Kivitz; Roy Fleischmann; Robert Inman; Wayne Tsuji
Journal:  Arthritis Rheum       Date:  2003-11

10.  Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

Authors:  J Brandt; A Khariouzov; J Listing; H Haibel; H Sörensen; L Grassnickel; M Rudwaleit; J Sieper; J Braun
Journal:  Arthritis Rheum       Date:  2003-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.